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Transition metal-catalysed A-ring C–H activations and C(sp2)–C(sp2) couplings in
the 13a-oestrone series and in vitro evaluation of antiproliferative properties
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Szeged, Szeged, Hungary; cDepartment of Medicinal Chemistry, University of Szeged, Szeged, Hungary; dInstitute of Biochemistry, Faculty of
Medicine, University of Ljubljana, Ljubljana, Slovenia
ABSTRACT
Facile syntheses of 3-O-carbamoyl, -sulfamoyl, or -pivaloyl derivatives of 13a-oestrone and its 17-deoxy
counterpart have been carried out. Microwave-induced, Ni-catalysed Suzuki–Miyaura couplings of the
newly synthesised phenol esters with phenylboronic acid afforded 3-deoxy-3-phenyl-13a-oestrone deriva-
tives. The carbamate and pivalate esters proved to be suitable for regioselective arylations. 2-(4-
Substituted) phenyl derivatives were synthesised via Pd-catalysed, microwave-assisted C–H activation reac-
tions. An efficient, one-pot, tandem methodology was elaborated for the introduction of the carbamoyl or
pivaloyl group followed by regioselective C-2-arylation and subsequent removal of the directing group.
The antiproliferative properties of the novel 13a-oestrone derivatives were evaluated in vitro on five
human adherent cancer cell lines of gynaecological origin. 3-Sulfamate derivatives displayed substantial
cell growth inhibitory potential against certain cell lines. The newly identified antiproliferative compounds
having hormonally inactive core might be promising candidates for the design of more active anti-
cancer agents.
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At the beginning of the 2000s, transition metals and, in particular,
palladium came into focus in regard to the development of car-
bon–carbon coupling reactions. In principle, palladium is one of
the few metals, which has a unique ability to activate various
organic compounds. Essentially, two molecules are brought close
to each other via forming metal–carbon bonds. The two partners
couple together through establishing a new carbon–carbon single
bond1. The significance of palladium-catalysed C–C cross cou-
plings was highlighted by the shared Nobel Prize in Chemistry in
2010. Richard F. Heck, Ei-ichi Negishi, and Akira Suzuki received
the Prize for “palladium-catalysed cross couplings in organic syn-
thesis”2. These cross-coupling reactions have found remarkable
utility in the synthesis of natural products and biologically active
compounds. A wide range of their applications in the pharmaceut-
ical industry increased their value even more. These coupling
reactions are catalysed by zerovalent palladium, utilising organo-
halides as electrophilic and organometallic compounds as nucleo-
philic partners. Suzuki coupling facilitates the synthesis of biaryl
compounds by employing organoboron nucleophiles3. Recently,
direct arylations have come in the focus of attention. Aromatic
C–H activation allows the formation of biaryl derivatives by avoid-
ing the use of an organometallic nucleophilic partner. Palladium-
catalysed chelation-directed C–H activations of phenol derivatives
utilise “directing groups (DGs)”, which facilitate and direct the sub-
stitution in a regioselective manner. Literature describes several
nitrogen-containing DGs, such as N-heterocycles, amides, imines,
and amines4–8. In order to broaden the applicability of chelation-
directed C–H activations, other types of substrates have been
applied as well. Phenol esters9–13 offer a good alternative, owing
to their usability under mild conditions (Scheme 1). Carbamates,
sulfamates, or pivalates have already been examined as DGs in
Pd-catalysed ortho-arylation of phenols4,10. These DGs are readily
prepared, robust, easily removable, and might show important
biological properties on their own right10. It should be emphas-
ised that these phenolic derivatives are generally stable under Pd-
catalysed reaction conditions10–13. Beside the synthetic advantages
of aryl carbamates, sulfamates, or pivalates in directed C–H activa-
tions, these phenol derivatives are popular coupling partners in
cross-coupling reactions (Scheme 1)9,14. The oxygen-based electro-
philes provide a greener alternative to commonly used organoha-
lides, since the halide-containing waste is avoided. Concerning the
hydrolytic properties of the O-acylated phenol derivatives, the
robust pivalate esters appear to be the right choice. Pivalates are
attractive candidates considering cost and they are useful in both
academic and industrial applications15. The pronounced stability
of carbamates and sulfamates allows their application in coupling
reactions using heterocyclic boronic acids9. Boronic acids are
beneficial coupling partners in Suzuki–Miyaura reactions, owing to
their wide availability, low toxicity, high stability, and broad func-
tional group tolerance. Ni- or Fe-catalysed C(sp2)–C(sp2) couplings
of the mentioned phenol derivatives with boronic acids or aryl tri-
fluoroborates are known in the literature9,14,16. The methodology
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based on Ni-catalysed coupling of halogen-free substrates
described recently, applying non-toxic boronic acids in green sol-
vents, might find application even in industry9.
We have recently described Pd-catalysed cross couplings at the
C-2 or C-4 position of the 13a-estrane core (Scheme 2)17–20.
Starting from steroidal aryl halides (5–7), microwave-assisted C–C,
C–N, or C–P couplings were performed. The 2-(substituted 4-phe-
nyl) moiety was attached to the A-ring of the steroid via
C(sp2)–C(sp2) or C(sp2)–C(sp) coupling. Suzuki–Miyaura reactions
were carried out using substituted phenylboronic acids as
reagents leading to biphenyl derivatives (8–10, Y═Ph)17. The indir-
ect introduction of a phenyl group was performed in Sonogashira
reactions through a linear CC linker, furnishing phenylethynyl
derivatives (8–10, Y═PhCC)18. The Buchwald–Hartwig aminations
of the bromoarene substrates (5–7) with aniline derivatives led to
phenylamino compounds (8–10, Y═PhNH)19. The Hirao couplings
facilitated the functionalisation of the A-ring with substituents dif-
fering in size and polarity20. Steroidal phosphonates and tertiary
phosphine oxide derivatives (8–10, Y═P(O)Z2) were synthesised. In
addition to positions C-2 or C-4, the 3-OH group was also modi-
fied by synthesising 3-O-alkyl and 3-O-aralkyl derivatives. The
majority of 13a-oestrone derivatives modified in the A-ring proved
to be biologically active. Certain biphenyl derivatives displayed
substantial antiproliferative action against human reproductive
cancer cell lines17. The 3-hydroxy-2-phenylethynyl compounds
exerted marked inhibitory action against 17b-hydroxysteroid
dehydrogenase 1 enzyme (17b-HSD1), which catalyses the last
step of oestradiol biosynthesis18. C-2 phosphonated derivatives
proved to be dual organic anion-transporting polypeptide
(OATP2B1) and 17b-HSD1 inhibitors20. OATP2B1 is a membrane
transporter facilitating the cellular uptake of various endogenous
compounds, drugs, and hormonal steroids21–23. Since increased
uptake of hormones by OATP2B1 might lead to marked tumour
proliferation, inhibition of the transporter might be a powerful
antitumoural approach24,25. It should be underlined that the bio-
logical activity of 13a-oestrone derivatives modified at the A-ring
greatly depends on the substitution pattern of the aromatic ring.
13a-Oestrone is readily available from natural oestrone, and this
core-modification results in marked decrease in the oestrogenic
effect26,27. The latter suggest that 13a-oestrone is a valuable start-
ing material in the design of bioactive oestrone-based agents lack-
ing oestrogenic side effects.
Encouraged by our recent results, here we report the synthesis
of 13a-oestrone carbamates, sulfamates, and pivalates suitable for
C–H activation and cross-coupling reactions. Our study included
microwave-assisted, Pd-catalysed regioselective ortho-arylations of
phenol esters. Phenylation at C-3 was performed via Ni-catalysed
Suzuki–Miyaura coupling using phenylboronic acid. Evaluation of
in vitro antiproliferative action of the newly synthesised com-
pounds against five human reproductive cancer cell lines was also
accomplished.
Materials and methods
Chemical syntheses, characterisation data of the reported com-
pounds, as well as experimental conditions of antiproliferative
assays performed are described in the Supporting Information.
Results and discussion
Chemistry
Modification of the phenolic hydroxyl function with DGs was car-
ried out starting from 13a-oestrone (11) or its 17-deoxy counter-
part (12, Scheme 3). Reactions of the steroidal substrates with
N,N-dimethylcarbamoyl chloride using sodium hydride as a base
afforded the desired carbamate esters (13, 14) in high yields.
Pivalate and sulfamate derivatives (15–20) were synthesised in a
microwave reactor. Esterifications of the substrates (11 or 12)
using pivaloyl chloride as a reagent and triethylamine and (4-
dimethylamino)pyridine as bases furnished the required pivalates
(17, 18) in excellent yields. Microwave irradiation of the starting
compounds (11 or 12) with sodium hydride and sulfamoyl or N,N-
dimethylsulfamoyl chloride yielded the corresponding sulfamates
(15, 16, 19, 20) in moderate to high yields.
There is information in the literature about the syntheses of 3-
deoxy-3-phenyl derivatives of natural oestrone, starting from its
trifluoromethanesulfonyl or triazinyl ester28–31. The cross-coupling
reactions of the esters with boronic acid derivatives afforded the
desired products. However, certain less common, but more robust
phenol derivatives might also be utilised as substrates in cross-
coupling reactions. Quasdorf et al. described Suzuki–Miyaura cou-
pling reactions of phenol carbamates, sulfamates, and piva-
lates32,33. The activation of a rather inert aryl C–O bond was
achieved via NiCl2(PCy3)2-promoted transformations. The couplings
with boronic acid reagents were accomplished under heating in
the temperature range of 110–150 C in 20–24 h.
Here, we performed C(sp2)–C(sp2) couplings of 13a-oestrone
esters according to the literature methodology32, but using micro-
wave heating (Scheme 4). The Ni-catalysed couplings of steroidal
substrates were carried out with phenylboronic acid as a reagent
and K3PO4 as the base in various solvents. The Ni(II) precatalyst
NiCl2(PCy3)2 is readily available and does not require glovebox
handling. Conversions of carbamates (13, 14) or sulfamates (15,
16) were appreciably higher in toluene; however, reactions of piv-
alates (17, 18) proceeded more effectively in acetonitrile. Reaction
times varied from 30 to 60min, depending on the nature of the
DG. The most significant improvement in reaction time was
observed in the case of pivalate (17, 18) couplings. Owing to
microwave irradiation, the reaction time could markedly be short-
ened, compared to those reported earlier applying other method-
ologies. It should be noted that 3-phenylation of 17-ketones took
place with higher conversions than those of their 17-deoxy coun-
terparts. The newly synthesised 3-deoxy-3-phenyl derivatives of
13a-oestrone (21, 22) might be interesting from biological point
of view. Biochemical investigations of the derivatives bearing a
large, apolar moiety at C-3 might provide valuable structure–activ-
ity relationship. The removal of one or both oxygen-containing
Scheme 1. Formation of biaryl products by catalytic cross coupling or directed
C–H activation.
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moieties (17-keto and/or 3-OH) might have great influence on the
biological activity of the compounds.
Phenylations of natural or 13a-oestrone derivatives at C-2 were
earlier carried out via Pd-catalysed cross-coupling reactions of ster-
oidal aryl halides with boronic acid reagents17,34,35. However, this
strategy requires multiple steps and prefunctionalisation of the
reagents. An alternative methodology, based on C–H activation,
might circumvent the inconveniences of cross-coupling reactions,
such as halogenation of the substrates and the use of organometal-
lic nucleophilic coupling partners. Regioselective C–H bond aryla-
tion of 3-carbamoylestrone with aryl iodides was described by
Bedford et al.36 In this transformation, Pd(OAc)2 was used as a cata-
lyst, AgOAc as a base in TFA solvent, and the mixture was stirred at
60 C for 18h. Arylation occurred at the C-2 ortho-position owing to
the directing ability of the carbamate group. The removal of the
DG was achieved in a subsequent step, by treatment with LiAlH4
followed by acidic hydrolysis. Note that not only 3-carbamoyles-
trone, but its 3-pivaloyl derivative also proved to be suitable for the
regioselective arylation via C–H activation. Palladium-catalysed
transformation of oestrone pivalate with the appropriate hyperva-
lent iodonium salt gave the 2-tolyl derivative37. The reaction mix-
ture was stirred at room temperature for 24h.
With these considerations in mind, here we intended to
explore the applicability of the earlier elaborated C–H activation
methodologies on the hormonally inactive 13a-oestrone, utilising
microwave irradiation (Scheme 5). The newly synthesised 3-carba-
moyl (13), -pivaloyl (17), or -sulfamoyl (15) 13a-oestrone deriva-
tives were selected as substrates. The rational of this choice
included both the DG ability of the mentioned 3-O-moieties and
their important potential biological activities in their own
right10,38,39. First, the transformation of 3-carbamoyl derivative 13
was carried out. As a first attempt, the combination of aryl iodide
(4 equiv.) and silver acetate (2 equiv.) was used with Pd(OAc)2
(10mol%) catalyst in TFA solvent. In earlier studies, this method-
ology proved to be suitable for ortho-arylation of anilides and O-
carbamoylphenols5,10,36. The reaction of compound 13 with iodo-
benzene was performed under both conventional heating and in
a microwave reactor at different temperatures. Microwave irradi-
ation markedly improved the efficiency of the C–H activations,
since conventional heating at 50 C gave only moderate yields of
the desired 23a product. Microwave heating at 50 C for 1 h, in
turn, afforded the best results in site-selective 2-phenylation with
both high product yields and high regio- and chemoselectivity.
Formation of neither the 4-phenyl regioisomer nor 2,4-bis prod-
ucts was observed. The explanation of exclusive 2-selectivity
might be the steric hindrance of the B-ring. Similar yields were
obtained under the same reaction conditions (time and tempera-
ture) by replacing AgOAc (2 equiv.) with Cs2CO3 (2 equiv.) or
K2CO3 (2 equiv.). Considering the price of the mentioned bases,
K2CO3 is the best choice.
When the reaction mixture submitted to a 1-h irradiation at
50 C was additionally exposed to a treatment at 150 C for 1 h,
complete removal of the DG occurred. Consequently, our present
microwave-assisted methodology allows one-pot ortho-arylation
and removal of the DG in a tandem reaction.
Next, we explored the reactions of 3-pivalate 17. Substrate 17
was subjected to C–H activation by utilising the microwave-
assisted methodology elaborated here. The desired 2-phenyl
derivative (24a) was obtained only in moderate yield. The pivalate
ester-directed approach seemed to be less efficient than that of
the carbamate. According to the literature, in the reaction of piva-
lates with hypervalent iodonium salts, acyloxy-directed Pd(II)-inser-
tion into the C–H bond of phenol derivatives might be promoted



































Scheme 3. Syntheses of 13a-oestrone carbamates (13, 14), pivalates (17, 18),
and sulfamates (15, 16, 19, 20). Reagents and conditions: (i) N,N-dimethylcarba-
moyl chloride (1.0 equiv.), NaH (1.3 equiv.), DMF, rt, 30min; (ii) pivaloyl chloride
(1.2 equiv.), DMAP (0.1 equiv.), NEt3 (1.2 equiv.), CH2Cl2, MW, 40 C, 1 h; (iii) N,N-
dimethylsulfamoyl chloride (1.0 equiv.), NaH (1.3 equiv.), toluene, MW, 100 C,
30min; (iv) sulfamoyl chloride (1.0 equiv.), NaH (1.3 equiv.), toluene, MW, 75 C

































Scheme 4. Syntheses of 3-deoxy-3-phenyl-13a-estrones (21, 22). Reagents and conditions: from carbamates (13 or 14): NiCl2(PCy3)2 (10mol%), phenylboronic acid
(4 equiv.), K3PO4 (7.2 equiv.), toluene, MW, 130 C, 1 h; from pivalates (17 or 18): NiCl2(PCy3)2 (10mol%), phenylboronic acid (4 equiv.), K3PO4 (7.2 equiv.), MeCN, MW,
75 C, 30min; from sulfamates (15 or 16): NiCl2(PCy3)2 (10mol%), phenylboronic acid (4 equiv.), K3PO4 (7.2 equiv.), toluene, MW, 130 C, 1 h.
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electrophilicity of the transition metal. However, in the case of
13a-oestrone pivalate 17, phenylation with iodobenzene did not
meet our expectations concerning product yield. If the reaction
mixture was exposed to an additional microwave irradiation at
100 C for 45min, the pivaloyl DG could completely be removed.
N,N-Dimethylsulfamoyl derivative 15 was also subjected to micro-
wave-assisted C–H activations with Pd(OAc)2 as catalyst; however,
no reaction occurred.
Next, we focussed on the synthesis of the 2-phenyl derivatives
(23–25) via an alternative approach. The facile, one-pot, micro-
wave-assisted methodology furnishing the 3-deprotected 2-phenyl
derivative (26a) allowed the synthesis of the desired 13a-oestrone
derivatives (23a–25a) in an indirect manner. 2-Phenyl-13a-oes-
trone (26a) was synthesised from its carbamate derivative (23a)
according to the MW procedure described above, and a pivalate
or a sulfamate DG was introduced in the next step. This two-step
reaction route provided the 2-phenyl-3-protected derivatives (24a,
25a) in high overall yields. Based on our recent publication, con-
cerning the promising antiproliferative action of 2-(4-chloro-
phenyl)-13a-oestrone (26b)17, arylations with 1-chloro-4-
iodobenzene were also performed. 2-(4-Chlorophenyl) derivatives
(23b–25b) were synthesised via the two-step reaction pathway
described above. C–H activations with Pd(OAc)2 as the catalyst,
starting from carbamate 13 or pivalate 17 and 1-chloro-4-iodo-
benzene as the reagent, under the above-described microwave
conditions, delivered the desired 2-(4-chlorophenyl) derivatives
(23b–25b) in high yields. The presence of chlorine at para pos-
ition relative to iodine seemed to be advantageous concerning
the yields of the desired products. The indirect approach for the
synthesis of 3-protected 2-substituted phenyl derivatives
(23b–25b) included the introduction of the DGs onto the phenolic
hydroxy function of compound 26b, synthesised from carbamate
13 (Scheme 5, vi–viii).
Pharmacology
The antiproliferative properties of the newly synthesised com-
pounds (13–25) and their parent derivatives 11 or 12 were inves-
tigated in vitro on a panel of human adherent cancer cell lines
representing the most relevant cancers of gynaecological origin.
The panel included different breast (MCF-7 and MDA-MB-231), cer-
vical (HeLa and SiHa), and ovarian (A278040,41) cancer cell lines.
While MCF-7 is an oestrogen receptor positive cell line, MDA-MB-
231 is lacking receptors for oestrogens, progesterone, and HER2
growth factor41–44. HeLa and SiHa differ in their HPV status: they
represent HPV-18 and HPV-16 positive cases, respectively45,46. The
determination of cell growth inhibitory action of test compounds
was performed by MTT assay47. The cancer selectivity of the most
effective derivatives was additionally determined by the same
method using NIH/3T3 mouse fibroblast cells.
We have recently reported the synthesis of potent antiprolifera-
tive core-modified oestrone derivatives obtained by inversion of
the C-13 configuration or opening the D-ring17,48–55. Certain test
compounds displayed submicromolar IC50 values, occasionally
with high cell line selectivity. The 13a- and/or D-seco compounds
possessed modifications mainly at positions C-2, C-4, and/or 3-OH.
It was shown that the nature, size, and polarity of the introduced
substituents greatly influence the cell growth inhibitory properties
of the compounds. 3-Hydroxy derivatives proved to be generally
less potent than their 3-ether counterparts. Introduction of a ben-
zyl or benzyltriazolyl group onto 3-OH improved the antiprolifera-
tive properties substantially51–55. Having found functional groups
responsible for the biological effect, we turned our attention to
attach all crucial structural elements to the hormonally inactive
13a-oestrone core. As a result, certain derivatives were identified
as dually acting agents, possessing both enzyme inhibitory and
antiproliferative properties20,55. We demonstrated that a few of
our potent anticancer compounds exert a direct effect on the
tubulin-microtubule system by increasing the rate of tubulin poly-

































Scheme 5. Syntheses of 2-(4-substituted phenyl)-13a-oestrone derivatives (23a,b–25a,b). Reagents and conditions: (i) carbamate 13, Pd(OAc)2 (10mol%), iodobenzene
(4 equiv.) or 1-chloro-4-iodobenzene (4 equiv.), K2CO3 (2 equiv.), TFA, MW, 50 C, 60min; (ii) pivalate 17, Pd(OAc)2 (10mol%), iodobenzene (4 equiv.) or 1-chloro-4-
iodobenzene (4 equiv.), K2CO3 (2 equiv.), TFA, MW, 50 C, 60min; (iii) sulfamate 15, Pd(OAc)2 (10mol%), iodobenzene (4 equiv.) or 1-chloro-4-iodobenzene (4 equiv.),
K2CO3 (2 equiv.), TFA, MW, 50 C, 60min; (iv) 2-phenyl carbamate 23a, TFA, MW, 150 C, 30min; (v) 2-phenyl pivalate 24a, TFA, MW, 100 C, 30min; (vi) 2-phenyl sulfa-
mate 25a, TFA, MW, 150 C, 30min; (vii) N,N-dimethylcarbamoyl chloride (1.0 equiv.), NaH (1.3 equiv.), DMF, rt, 30min; (viii) pivaloyl chloride (1.2 equiv.), DMAP
(0.1 equiv.), NEt3 (1.2 equiv.), CH2Cl2, MW, 40 C, 1 h; (ix) N,N-dimethylsulfamoyl chloride (1.0 equiv.), NaH (1.3 equiv.), toluene, MW, 100 C, 30min.
898 P. TRAJ ET AL.
for the design of oestrone-based potent anticancer agents, lacking
oestrogenic activity.
Concerning the modification of the phenolic hydroxy function
of oestrone derivatives, important structure–activity relationships
are described in the literature. Introduction of a sulfamoyl moiety
onto 3-OH of oestrogens resulted in compounds possessing
remarkable biological activities56–59. Their aryl O-sulfamate
pharmacophore facilitated steroid sulfatase inhibitory activity,
leading to anticancer effect. Nevertheless, certain oestrone sulfa-
mates proved to be active against triple-negative breast cancer
owing to their triple effect60. Beside their microtubule disruptor
properties, they displayed proapoptotic and anti-angiogenic
action60. Furthermore, carbamoylation of oestrogens at C-3-O
afforded N-mustard carbamates as potent cytotoxic agents against
prostatic adenocarcinoma61.
In addition to modifications at C-3, introduction of substituents
onto C-2 of the estrane core led to potent anticancer agents of
high value. 2-Halogenated and 2-phenylated derivatives were
identified as efficient inhibitors against enzymes involved in the
metabolism or biosynthesis of oestrogens34,62. It was highlighted
that 2-phenyl derivatives display potent CYP1B1 inhibitory
action34. CYP1B1 is responsible for the bioactivation of certain
procarcinogens, thereby catalysing the synthesis of mutagenic
compounds. The combination of a CYP1B1 inhibitor with an anti-
cancer agent might be suitable for the treatment of drug-resistant
cancers63,64. We recently described our results with respect to the
antiproliferative action of 2- or 4-(substituted phenyl)-13a-estrones
and their 3-benzyl ethers17. 2-(4-Chlorophenyl)-13a-oestrone was
found to be the most potent compound with low micromolar cell
growth inhibitory action against MCF-7 and HeLa cell lines. An
important structure–activity relationship was found, since the 3-
benzyl ether counterpart proved to be ineffective. A substantial
distinction was observed between the two pairs of breast and cer-
vical cancer cell lines, concerning the cell growth inhibitory action.
The triple negative breast and the HPV-16 positive cervical cell
lines seemed to be less sensitive to the test compound.
Taking into consideration of the above-mentioned promising
pharmacological properties of natural and 13a-oestrone deriva-
tives, here we combined the essential structural elements with the
aim of getting more potent antiproliferative agents and important
structure–activity relationship data. The key pharmacophores iden-
tified on the natural estrane core were transferred to the hormo-
nally inactive 13a-estone basic compound. Before testing the
newly designed derivatives, the cell growth inhibitory properties
of the starting 13a-oestrone (11) and its 17-deoxy counterpart
(12) were compared. As it can be seen in Table 1, compound 12
lacking the 17-keto group displayed stronger inhibitory actions
than 13a-oestrone 11. As a consequence, it seemed rational to
test the influence of the modification at the C-3-O group on both
17-keto and 17-deoxy core structures on the antitumoural action.
Carbamoylation leading to compounds 13 or 14 did not improve
the cell growth inhibitory properties. However, introduction of a
pivaloyl moiety seemed to lower the IC50 values of 17-deoxy
derivative 18 (against MCF-7 and HeLa). The most potent com-
pound group is represented by the 3-O-sulfamoyl derivatives.
Sulfamates bearing NH2-function (19, 20) generally exerted less
potent action, than the N,N-dimethyl derivatives (15, 16). The lat-
ter structural element, combined with a 17-keto group resulted in
a highly potent derivative (15). Phenylations at C-3 via
Suzuki–Miyaura coupling afforded 3-deoxy-3-phenyl derivatives
(21, 22), possessing weak antiproliferative action. These results
indicate that introduction of a large, apolar moiety onto C-3 by
the simultaneous removal of the oxygen-containing moiety is
rather disadvantageous concerning the cell growth inhibitory
action on the tested cell lines. Summarising the results obtained
for C-3-O-modified 13a-oestrone derivatives, it can be emphasised,
that the determined antiproliferative effect greatly depends on
the nature of introduced moieties. This screening suggests that
compound 15 is the most promising candidate for further
evaluations.
Determination of the antiproliferative activities of the newly
synthesised compounds was continued by testing 2-(substituted
4-phenyl)-13a-oestrone derivatives (23a,b–25a,b) bearing different
DGs. In the carbamate compound group (13; 23a,b), phenylations
did not improve the cytostatic properties. 2-Phenyl pivalate (24a)
displayed somewhat higher effect on MCF-7 cell line than that of
its 2-H counterpart (17). However, the sulfamate compound set
(15; 25a,b) provides interesting correlation results. It is worth
comparing the data obtained for the three 17-keto sulfamates,
namely, compound 15 with no modification at C-2 and the two 2-
phenyl derivatives (25a,b). There was no marked difference in the
effects exerted on the MCF-7 cell line: each compound displayed
high potency with IC50 values in the low micromolar range. HeLa
seemed to be correspondingly sensitive to the sulfamates, but the
cell growth inhibitory activity was improved by introducing the 4-
chlorophenyl moiety onto C-2. The most significant improvement
caused by 4-chlorophenylation was observed on SiHa and A2780
cell lines. The growth of HPV-16 positive cervical cells was sub-
stantially inhibited by compound 25b in a very low micromolar
range. To the best of our knowledge, this is the first 13a-oestrone
derivative with such a high potency against SiHa described in the
literature. This test compound, exerting outstanding activity
against both HPV-18 and HPV-16 positive cervical cancers, might
be of great importance in the design of anticancer agents target-
ing cervical carcinomas, since the majority of these carcinomas are
caused by these two types of HPV. For invasive cervical cancer,
HPV-16 is the most prevalent type (approximately 60%), HPV-18 is
the second (15%), and HPV-45 is the third most common type65.
With the aim of getting preliminary results concerning the
tumour selectivity of the detected action, certain test compounds
were additionally tested against a mouse fibroblast cell line (NIH/
3T3). 17-Deoxy-13a-oestrone 12 exerted the most potent antiproli-
ferative action against the NIH/3T3 cell line with an IC50 value of
15.29 mM. However, the rest of the test compounds influenced
the growth of the fibroblasts scarcely (less than 51% inhibition
even at 30 lM). It can be stated, that the NIH/3T3 cells are more
sensitive to reference agent cisplatin than to the 13a-oestrone
derivatives tested.
Conclusions
We introduced N- and/or O-containing DGs onto the phenolic
3-OH function of 13a-oestrone and its 17-deoxy counterpart.
The resulting carbamate, pivalate, or sulfamate esters proved to
be suitable for regioselective ortho-arylations via Pd-catalysed
C–H activation. A mild and efficient microwave-assisted method-
ology was elaborated. Arylation of a carbamate or pivalate and
the removal of the DG were achieved via a one-pot, tandem,
microwave procedure. The newly synthesised phenol esters
were suitable electrophilic substrates in microwave-induced, Ni-
catalysed Suzuki–Miyaura couplings with phenylboronic acid as
a nucleophilic reagent. Biphenyl derivatives formed by
C(sp2)–C(sp2) couplings represent an interesting novel class of
13a-estrane derivatives lacking one or two oxygen-containing
functionalities. The antitumoural properties of the newly syn-
thesised 13a-oestrone derivatives were determined in vitro on
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five human cancer cell lines of gynaecological origin. Certain
potent antiproliferative compounds were identified and import-
ant structure–activity relationships were established. Sulfamate
derivatives seemed to be superior concerning their substantial
antiproliferative potential. 2-(4-Chlorophenyl)-13a-oestrone sulfa-
mate 25b displayed outstanding growth inhibitory action
against the two cervical cancer cell lines with different HPV-sta-
tus. The presence of an N,N-dimethylsulfamate pharmacophore
together with the 2-(4-chlorophenyl) moiety improved the anti-
tumoural action. Considering that HPV-16 and HPV-18 play a
causative role in the majority of cervical cancer cases, newly
identified 25b with its hormonally inactive core might be a
promising candidate in the design of new anticancer agents
acting selectively.
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